Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts, including two podium presentations, at the American Association for Cancer Research Annual Meeting on April 17-22, 2026 in San Diego. Highlights include MONITOR-Breast neoadjuvant ctDNA dynamics and a phase II adjuvant PD-1 trial, plus four poster presentations and a booth exhibit.
The company will showcase its Precise MRD tumor-informed MRD assay, MyRisk Hereditary Cancer Test with RiskScore, Prolaris, MyChoice CDx, and partnership offerings in biopharma development.
Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026. The approval adds tumor-based HRD/BRCA testing access beyond prior breast and ovarian coverage under Japan's NHI.
This expands testing options for patients with metastatic castration-resistant prostate cancer and may increase identification of PARP inhibitor candidates in Japan.
Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval of the MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer in the United States. The approval is based on final PRIMA trial data and establishes MyChoice CDx as the only FDA-authorized CDx for Zejula.
The test uses next-generation sequencing to assess BRCA1/2 (including large rearrangements) and a tumor genomic instability score (LOH, TAI, LST) to determine HRD status for treatment decisions.
Myriad (NASDAQ: MYGN) launched the Precise MRD tumor-informed circulating tumor DNA (ctDNA) test on March 2, 2026, with a select group of community oncologists for patients with breast cancer.
The assay uses whole-genome sequencing to create personalized tests and enables ultrasensitive ctDNA detection down to one part per million. Myriad plans a broader U.S. commercial rollout later in 2026, with no limit on participating patients in the initial release.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.
Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.
Myriad Genetics (NASDAQ: MYGN) reported Q4 2025 revenue of $209.8 million and full‑year 2025 revenue of $824.5 million (down 2% YoY). Test volume was 382,000 in Q4, up 2% YoY. Q4 GAAP net loss was $7.9 million; adjusted EBITDA was $14.3 million. The company reiterated 2026 guidance of $860–$880 million revenue and 68–69% adjusted gross margin, with adjusted EBITDA guidance of $37–$49 million.
Management highlighted Prolaris, GeneSight, and three planned 2026 test launches (Precise MRD, AI-enabled Prolaris, FirstGene) as drivers for growth.
Myriad Genetics (NASDAQ: MYGN) announced publication of the analytical validation of the FirstGene Multiple Prenatal Screen in Clinical Chemistry on February 19, 2026. Using nearly 500 samples, the study reported each test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity.
The assay evaluates fetal aneuploidy, RhD compatibility, and recessive condition status for the pregnant person and fetus across 19 prevalent severe conditions. The test uses fetal-fraction amplification and a trajectory analysis algorithm to improve genotype resolution and reproducibility, which the company says supports broader commercialization efforts.
Myriad Genetics (NASDAQ: MYGN) will release its fourth quarter and full year 2025 financial results and hold an earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The earnings release will be issued after market close the same day.
Management will provide a financial overview and business update; a live webcast and archived replay will be available at the company's Investor Relations website. Company executives will also appear at three investor healthcare conferences in March 2026.
Myriad Genetics (NASDAQ: MYGN) plans a limited clinical launch of Precise MRD in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later in 2026, with potential further expansion in 2027.
Key study data show ultrasensitive ctDNA detection down to 1 part-per-million, 93% baseline sensitivity in MONITOR-Breast, and 100% baseline detection plus 100% one-month post-surgery sensitivity for recurrence prediction in MONSTAR-SCREEN-3; one-month postoperative ctDNA positivity was linked to shorter disease-free survival (median follow-up ~6 months, p<0.001).